<DOC>
	<DOC>NCT01302938</DOC>
	<brief_summary>To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design</brief_summary>
	<brief_title>Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Female and 21 years or older Overactive bladder symptoms (subjectreported) for at least 3 months Be resident in the United States of America and have access and be able to use a computer with internet access throughout the duration of the study Clinically significant hepatic, renal or neurological condition such as stroke (with residual deficit), multiple sclerosis, spinal cord injury, or Parkinson's disease. History of cystitis, continence, urogenitalcancer or radiation Subjects who are pregnant, nursing, or with a positive urine pregnancy test or who are intending to become pregnant within 28 days after the completion of the trial.</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Double-blind</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>frequency</keyword>
	<keyword>urgency</keyword>
	<keyword>web-based</keyword>
	<keyword>incontinence</keyword>
	<keyword>methodology</keyword>
	<keyword>ediary</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability ER</keyword>
	<keyword>overactive bladder</keyword>
</DOC>